*Comparative clinical significance is unknown.
Regular benefit (Alberta Health Care Insurance Plan)2
For more information about the listing please see the Alberta Drug Benefit List here
General benefit (no codes) with the following therapeutic note:3
For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy.
For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
For more information about the listing please contact ODB here
For more information about the listing please contact NB Formulary here
For more information about the listing please see the Newfoundland and Labrador Prescription Drug Program here
Exception status benefit with criteria6
For the treatment of body and scalp psoriasis after failure of a topical steroid and a vitamin D analogue as single agents.
For more information about the listing please see the Nova Scotia Formulary Updates here
Exceptional Medications by RAMQ8
For the treatment of plaque psoriasis in persons for whom control of the disease is insufficient despite the use of a vitamin D analogue OR a medium or high potency topical corticosteroid.†
Write code DE 128 for reimbursement
†Codes des Médicaments d’exception publiés par la Régie de l’assurance maladie du Québec. Bibliothèque et Archives nationales du Québec, 2019. Accessed online April 2019 at: https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/codes-medicaments-exception/codes_medicaments_exception.pdf.
Non-Insured Health Benefits (NIHB)
on Non-Insured Health Benefits (NIHB) which provides reimbursement for Registered First Nations and Inuit individuals across Canada.9
Enstilar® Safety Information
Indication and Clinical Use:
Enstilar® is indicated for the topical treatment of psoriasis vulgaris in adults for up to 4 weeks.
The use in pediatrics (<18 years of age) is not recommended as safety and efficacy have not been established in this population.
● Disorders of calcium metabolism
● Viral skin lesions; fungal, bacterial, parasitic skin infections; skin manifestations related to tuberculosis
● Perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds
● Erythrodermic and pustular psoriasis
Relevant warnings and precautions:
● Long-term or concomitant corticosteroid use
● Use with ultraviolet radiation
● Avoid use on broken skin, on mucous membranes, in skin folds, or under occlusive dressing
● Hypercalcemia and hypercalciuria
● Hepatic or renal impairment
● Avoid ophthalmic use
● Avoid use on face, axillae, flexures, groin, or genitals
● Use caution in pregnant patients
● Avoid use on breast if breastfeeding
● Use in children <18 years of age or the elderly ≥65 years of age
For more information:
Please consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available by calling LEO Pharma Medical Information at 1-800-263-4218.
© 2020 LEO Pharma Inc. All rights reserved.
® Registered trademark of LEO Pharma A/S used under license
and distributed by LEO Pharma Inc.
- IQVIA GPM TRX Audit. April 2020.
- Alberta Health. Available at www.alberta.ca/drug-benefit-list-and-drug-review-process.aspx. Accessed April 2019.
- Ontario Formulary. Available at www.ontario.ca/page/check-medication-coverage. Accessed April 2019.
- New Brunswick Drug Plans Formulary. June 2019.
- Newfoundland and Labrador Prescription Drug Program Coverage Status. June 2019.
- Nova Scotia Formulary. June 2019.
- Saskatchewan Online Formulary Database. Available at https://formulary.drugplan.ehealthsask.ca. Accessed April 2019.
- Régie de l’assurance maladie du Québec (RAMQ). Codes des medicaments d’exception. 2019.
- Non-Insured Health Benefits (NIHB). Drug Benefit List. June 2019.